485 related articles for article (PubMed ID: 11694792)
1. Role of Herceptin in primary breast cancer: views from North America and Europe.
Leyland-Jones B; Smith I
Oncology; 2001; 61 Suppl 2():83-91. PubMed ID: 11694792
[TBL] [Abstract][Full Text] [Related]
2. Interaction between Herceptin and taxanes.
Diéras V; Beuzeboc P; Laurence V; Pierga JY; Pouillart P
Oncology; 2001; 61 Suppl 2():43-9. PubMed ID: 11694787
[TBL] [Abstract][Full Text] [Related]
3. The predictive value of HER2 in breast cancer.
Piccart M; Lohrisch C; Di Leo A; Larsimont D
Oncology; 2001; 61 Suppl 2():73-82. PubMed ID: 11694791
[TBL] [Abstract][Full Text] [Related]
4. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials.
Baselga J
Oncology; 2001; 61 Suppl 2():14-21. PubMed ID: 11694783
[TBL] [Abstract][Full Text] [Related]
5. First-line Herceptin monotherapy in metastatic breast cancer.
Vogel CL; Cobleigh MA; Tripathy D; Gutheil JC; Harris LN; Fehrenbacher L; Slamon DJ; Murphy M; Novotny WF; Burchmore M; Shak S; Stewart SJ
Oncology; 2001; 61 Suppl 2():37-42. PubMed ID: 11694786
[TBL] [Abstract][Full Text] [Related]
6. Future directions in the adjuvant treatment of breast cancer: the role of trastuzumab.
Smith I
Ann Oncol; 2001; 12 Suppl 1():S75-9. PubMed ID: 11521726
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
Baselga J; Perez EA; Pienkowski T; Bell R
Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
[TBL] [Abstract][Full Text] [Related]
8. HER2-positive breast cancer: update on Breast Cancer International Research Group trials.
Nabholtz JM; Reese DM; Lindsay MA; Riva A
Clin Breast Cancer; 2002 Oct; 3 Suppl 2():S75-9. PubMed ID: 12435291
[TBL] [Abstract][Full Text] [Related]
9. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
Mallmann P
Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
[No Abstract] [Full Text] [Related]
10. Herceptin (trastuzumab): adjuvant and neoadjuvant trials.
Yaal-Hahoshen N; Safra T
Isr Med Assoc J; 2006 Jun; 8(6):416-21. PubMed ID: 16833172
[No Abstract] [Full Text] [Related]
11. [Docetaxel (Taxotere) in combination with trastuzumab (Herceptin)].
Ficorella C
Tumori; 2001; 87(1 Suppl 2):S10-8. PubMed ID: 11357872
[No Abstract] [Full Text] [Related]
12. HER-2/neu expression in primary and metastatic breast cancer.
Lower EE; Glass E; Blau R; Harman S
Breast Cancer Res Treat; 2009 Jan; 113(2):301-6. PubMed ID: 18273700
[TBL] [Abstract][Full Text] [Related]
13. [Docetaxel (Taxotere) in combination with anthracycline, capecitabin (Xeloda) and new drugs].
Galligioni E
Tumori; 2001; 87(1 Suppl 2):S1-9. PubMed ID: 11357871
[No Abstract] [Full Text] [Related]
14. Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer.
Cook-Bruns N
Oncology; 2001; 61 Suppl 2():58-66. PubMed ID: 11694789
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of Herceptin in women with metastatic breast cancer: results from pivotal clinical studies.
Smith IE
Anticancer Drugs; 2001 Dec; 12 Suppl 4():S3-10. PubMed ID: 11989525
[TBL] [Abstract][Full Text] [Related]
16. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies.
Singer CF; Köstler WJ; Hudelist G
Biochim Biophys Acta; 2008 Dec; 1786(2):105-13. PubMed ID: 18375208
[TBL] [Abstract][Full Text] [Related]
17. A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.
Yardley D; Burris H; Peacock N; Raefsky E; Melnik M; Inhorn R; Shipley D; Hainsworth J
Breast Cancer Res Treat; 2010 Sep; 123(2):471-5. PubMed ID: 20658263
[TBL] [Abstract][Full Text] [Related]
18. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials.
Slamon D; Pegram M
Semin Oncol; 2001 Feb; 28(1 Suppl 3):13-9. PubMed ID: 11301370
[TBL] [Abstract][Full Text] [Related]
19. [Breast cancer: HER2 changes one's cards on the table].
Lopez M
Clin Ter; 2005; 156(5):255-62. PubMed ID: 16382976
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the Retreatment after HErceptin Adjuvant trial.
Láng I; Bell R; Feng FY; Lopez RI; Jassem J; Semiglazov V; Al-Sakaff N; Heinzmann D; Chang J
Clin Oncol (R Coll Radiol); 2014 Feb; 26(2):81-9. PubMed ID: 24051172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]